XL019 Chemical Properties

storage temp. 

Store at -20°C

solubility 

insoluble in EtOH; insoluble in H2O; ≥11.125 mg/mL in DMSO

form 

solid

color 

Green to yellow

XL019 Usage And Synthesis

Uses

XL019 is used in the synthesis of JAK-2 modulators for the treatment of related diseases.

Biological Activity

XL019 is an ATP-binding site-targeting, orally active JAK2 subtype-selective Janus kinase inhibitor (IC50 in nM = 2.2/JAK2 vs. 134.3/JAK1, 214.2/JAK3, 348.3/TYK2) with much reduced or little activity against 116 other kinases (IC50 in nM = 125.4/PDGFRB, 139.7/FLT3, 225.8/c-KIT, 313.8/p70S6K, 370/MLK1, 375.4/IKKbeta, 483.6/KDR, 546.7/PDGFRA, 554.5/FLT4, 910.5/FLT; IC50 >1 μM toward remaining 106 kinases), CYP (1A2, 2C9, 2D6, 3A4 IC50 ≥20 μM), hERG (IC50 = 16 μM), and P-glycoprotein (IC50 >20 μM). XL019 effectively inhibits cellular STAT1/STAT3 phosphorylation both in HEL92.1.7 cultures (IC50 in nM = 386.4/pStat1 and 695/pStat3) and in HEL92.1.7 xenograft-derived tumor in mice in vivo (oral ED50 in mg/kg = 42/pStat1 and 210/pStat3) with significant HEL92.1.7 tumor suppression efficacy in mice (by 60% and 70% on day 14, respectively, with 200 and 300 mg/kg bid p.o. dosage).

target

JAK2

XL019(945755-56-6)Related Product Information

• XL518
• 5-Bromo-4-chloro-3-indolyl-beta-D-galactoside
• 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[7-methoxy-6-[(methylamino)carbonyl]-4-quinolinyl]oxy]phenyl]-
• 3-Pyrrolidinecarboxylic acid
• 3-Cyano-pyrrolidine hydrochloride
• pilaralisib
• Cabozantinib
• BMS 833923
• XL147
• XL413 (BMS-863233)
• BMS-852927
• 2-methoxyethyl 4-((4-(4-chlorophenoxy)-3,5-difluorophenyl)sulfonyl)-3-(hydroxycarbamoyl)piperazine-1-carboxylate
• XL888
• XL-388
• XL 228
• XL-765,SAR245409
• 3-(3,4-Difluorobenzoyl)-1,2,3,6-tetrahydro-1,1-dimethylazepino[4,5-b]indole-5-carboxylic acid 1-methylethyl ester
• XL-652